<p>恩辛峰峰顾问公司在第二季度减持了碧迪医疗公司（Becton, Dickinson and Company，NYSE:BDX - Free Report）的股份，根据该公司最近向证券交易委员会（SEC）披露的信息，持有该医疗器械供应商的股票 156,408 股，比期间减持了 15,297 股。恩辛峰峰顾问公司在最近一个季度结束时持有碧迪医疗公司 0.05% 的股份，价值 3655.4 万美元。</p>
<p>其他大型投资者最近也调整了对该公司的持股。利维斯伯格金融咨询公司在第四季度新建了一份碧迪医疗公司的头寸，价值约 27000 美元。OLD Point Trust &amp; Financial Services N A 在第四季度购入了碧迪医疗公司的新股，价值约 29000 美元。斯卡伯勒顾问有限责任公司在第四季度新建了一份碧迪医疗公司的头寸，价值约 32000 美元。莱斯顾问有限责任公司在第一季度购入了碧迪医疗公司的新头寸，价值约 38000 美元。最后，ICA 集团财富管理有限责任公司在第四季度购入了碧迪医疗公司的新股，价值约 42000 美元。86.97% 的股份由机构投资者持有。</p>
<h2>分析师的升级和降级</h2>
<p>几位研究分析师对 BDX 股票发表了意见。StockNews.com 在 8 月 8 日星期四的一份研究报告中，将碧迪医疗公司的评级从 “持有” 调升至 “买入”。高盛集团在 5 月 30 日星期四对碧迪医疗公司的股票进行了覆盖。他们给出了一份 “买入” 评级和 274.00 美元的价格目标。雷蒙德詹姆斯将碧迪医疗公司的目标股价从 275.00 美元降至 270.00 美元，并在 8 月 2 日星期五的一份研究报告中给出了 “表现优异” 的评级。花旗集团将碧迪医疗公司的股票价格目标从 260.00 美元降至 255.00 美元，并在 7 月 10 日星期三的一份研究报告中为该公司设定了 “中性” 评级。最后，斯蒂弗尔尼古拉斯将碧迪医疗公司的股票价格目标从 270.00 美元上调至 280.00 美元，并在 7 月 26 日星期五的一份研究报告中给出了 “买入” 评级。一位股票研究分析师给出了持有评级，而八位则给出了买入评级。根据 MarketBeat.com 的数据，碧迪医疗公司目前的共识评级为 “中等买入”，平均目标股价为 279.50 美元。</p>
<p><strong>查看我们对碧迪医疗公司的最新报告</strong></p>
<h2>碧迪医疗公司股价下跌 0.5%</h2>
<p>纽约证券交易所（NYSE）BDX 周五开盘价为 233.50 美元。该公司的 50 天移动平均股价为 235.51 美元，200 天移动平均股价为 235.54 美元。该股的市值为 674.8 亿美元，市盈率为 51.43，PEG 比率为 1.91，贝塔系数为 0.42。碧迪医疗公司的 52 周最低价为 218.75 美元，最高价为 269.52 美元。该公司的资产负债比为 0.70，流动比率为 1.85，速动比率为 1.36。</p>
<p>碧迪医疗公司（NYSE:BDX - Get Free Report）于 8 月 1 日星期四公布了季度财报。该医疗器械供应商在该季度报告中每股盈利 3.50 美元，超过了市场预期的 3.31 美元，增加了 0.19 美元。该季度业务收入为 49.9 亿美元，低于市场预期的 50.8 亿美元。碧迪医疗公司的净资产收益率为 14.49%，净利润率为 7.13%。相比去年同期，碧迪医疗公司的季度收入增长了 2.3%。分析师预计，碧迪医疗公司本财年的每股收益将达到 13.1 美元。</p>
<h2>碧迪医疗公司宣布股息</h2>
<p>该公司最近宣布了季度股息，将于 9 月 30 日星期一支付。股东登记日为 9 月 9 日星期一，将支付 0.95 美元的股息。除息日为 9 月 9 日星期一。这代表年化股息为 3.80 美元，股息率为 1.63%。碧迪医疗公司的派息比率目前为 83.70%。</p>
<h2>碧迪医疗公司简介（免费报告）</h2>
<p>碧迪医疗公司在全球范围内为医疗机构、医生、生命科学研究人员、临床实验室、制药行业和普通公众开发、制造和销售医疗用品、设备、实验室设备和诊断产品。该公司分为 BD Medical、BD Life Sciences 和 BD Interventional 三个部门运营。</p>
<h2>精选文章</h2>
<ul>
<li>我们喜欢的五只股票，比碧迪医疗公司更好</li>
<li>什么是 FAANG 股票，它们是好投资吗？</li>
<li>利用村庄农场股票，随着大麻市场的发展</li>
<li>比较和交易高市盈率股票</li>
<li>MarketBeat 周评 - 9/16 - 9/20</li>
<li>投资咖啡的三种方式，除了喝</li>
<li>秋季收益不容错过的 3 只零售股</li>
</ul>
<p><strong>想看看其他对 BDX 持股的对冲基金？</strong> 访问 HoldingsChannel.com 获取最新的 13F 申报和内部交易信息，了解碧迪医疗公司（NYSE:BDX - Free Report）。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJEWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJEWA"/></p>
<p><em>这则即时新闻警报是由叙事科技和 MarketBeat 的金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<p>→ 这个价值 15 美元的&#34;内幕秘密&#34;可能拯救您的退休金（来自市场幕后）(广告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NDUx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NDUx"/></p>
<h2>现在是否值得投资 1,000 美元到碧迪医疗？</h2>
<p>在您考虑是否投资碧迪医疗之前，您应该听听这个消息。</p>
<p>MarketBeat 持续追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该购买的股票... 而碧迪医疗并不在名单上。</p>
<p>尽管碧迪医疗目前在分析师中拥有&#34;中等买入&#34;评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

碧迪医疗

<p>Ensign Peak Advisors Inc 在第二季度减持了碧迪医疗（Becton, Dickinson and Company，NYSE:BDX）8.9％的股份，现持有 156,408 股，价值约为$554,000。该公司已经看到多家机构投资者调整其持股。分析师们给予 BDX 股票 “中等买入” 的共识评级，平均目标价为$250.50。碧迪医疗报告第二季度每股盈利为$1.50，超出预期，并宣布每股$0.95 的季度股息，将于 9 月 30 日支付</p>

<p>Ensign Peak Advisors Inc reduced its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 8.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 156,408 shares of the medical instruments supplier's stock after selling 15,297 shares during the period. Ensign Peak Advisors Inc owned 0.05% of Becton, Dickinson and Company worth $36,554,000 at the end of the most recent quarter.</p>
<ul>
<li>Intuitive Surgical Gives Buying Opportunity Off Its 52 Week Highs</li>
</ul>
<div class="lb-trans"><p>恩辛峰峰顾问公司在第二季度减持了碧迪医疗公司（Becton, Dickinson and Company，NYSE:BDX - Free Report）的股份，根据该公司最近向证券交易委员会（SEC）披露的信息，持有该医疗器械供应商的股票 156,408 股，比期间减持了 15,297 股。恩辛峰峰顾问公司在最近一个季度结束时持有碧迪医疗公司 0.05% 的股份，价值 3655.4 万美元。</p>
</div><p>Other large investors also recently modified their holdings of the company. Livelsberger Financial Advisory acquired a new position in Becton, Dickinson and Company in the 4th quarter valued at about $27,000. OLD Point Trust &amp; Financial Services N A bought a new stake in shares of Becton, Dickinson and Company during the fourth quarter worth approximately $29,000. Scarborough Advisors LLC acquired a new position in shares of Becton, Dickinson and Company in the fourth quarter valued at approximately $32,000. Rise Advisors LLC bought a new position in shares of Becton, Dickinson and Company during the first quarter worth approximately $38,000. Finally, ICA Group Wealth Management LLC acquired a new stake in Becton, Dickinson and Company during the 4th quarter worth approximately $42,000. 86.97% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他大型投资者最近也调整了对该公司的持股。利维斯伯格金融咨询公司在第四季度新建了一份碧迪医疗公司的头寸，价值约 27000 美元。OLD Point Trust &amp; Financial Services N A 在第四季度购入了碧迪医疗公司的新股，价值约 29000 美元。斯卡伯勒顾问有限责任公司在第四季度新建了一份碧迪医疗公司的头寸，价值约 32000 美元。莱斯顾问有限责任公司在第一季度购入了碧迪医疗公司的新头寸，价值约 38000 美元。最后，ICA 集团财富管理有限责任公司在第四季度购入了碧迪医疗公司的新股，价值约 42000 美元。86.97% 的股份由机构投资者持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师的升级和降级</h2>
</div><p>Several research analysts have weighed in on BDX shares. StockNews.com upgraded Becton, Dickinson and Company from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Thursday, August 8th. The Goldman Sachs Group began coverage on shares of Becton, Dickinson and Company in a research note on Thursday, May 30th. They issued a &#34;buy&#34; rating and a $274.00 price objective for the company. Raymond James decreased their target price on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an &#34;outperform&#34; rating on the stock in a research report on Friday, August 2nd. Citigroup dropped their price target on shares of Becton, Dickinson and Company from $260.00 to $255.00 and set a &#34;neutral&#34; rating for the company in a research report on Wednesday, July 10th. Finally, Stifel Nicolaus increased their price target on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, July 26th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $279.50.</p>
<ul>
<li>Healthcare Stocks With at Least 30 Years of Dividend Increases</li>
</ul>
<div class="lb-trans"><p>几位研究分析师对 BDX 股票发表了意见。StockNews.com 在 8 月 8 日星期四的一份研究报告中，将碧迪医疗公司的评级从 “持有” 调升至 “买入”。高盛集团在 5 月 30 日星期四对碧迪医疗公司的股票进行了覆盖。他们给出了一份 “买入” 评级和 274.00 美元的价格目标。雷蒙德詹姆斯将碧迪医疗公司的目标股价从 275.00 美元降至 270.00 美元，并在 8 月 2 日星期五的一份研究报告中给出了 “表现优异” 的评级。花旗集团将碧迪医疗公司的股票价格目标从 260.00 美元降至 255.00 美元，并在 7 月 10 日星期三的一份研究报告中为该公司设定了 “中性” 评级。最后，斯蒂弗尔尼古拉斯将碧迪医疗公司的股票价格目标从 270.00 美元上调至 280.00 美元，并在 7 月 26 日星期五的一份研究报告中给出了 “买入” 评级。一位股票研究分析师给出了持有评级，而八位则给出了买入评级。根据 MarketBeat.com 的数据，碧迪医疗公司目前的共识评级为 “中等买入”，平均目标股价为 279.50 美元。</p>
</div><p><strong>View Our Latest Report on Becton, Dickinson and Company</strong></p>
<div class="lb-trans"><p><strong>查看我们对碧迪医疗公司的最新报告</strong></p>
</div><h2>Becton, Dickinson and Company Stock Down 0.5 %</h2>
<div class="lb-trans"><h2>碧迪医疗公司股价下跌 0.5%</h2>
</div><p>NYSE BDX opened at $233.50 on Friday. The business has a fifty day moving average price of $235.51 and a two-hundred day moving average price of $235.54. The stock has a market capitalization of $67.48 billion, a PE ratio of 51.43, a PEG ratio of 1.91 and a beta of 0.42. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $269.52. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36.</p>
<div class="lb-trans"><p>纽约证券交易所（NYSE）BDX 周五开盘价为 233.50 美元。该公司的 50 天移动平均股价为 235.51 美元，200 天移动平均股价为 235.54 美元。该股的市值为 674.8 亿美元，市盈率为 51.43，PEG 比率为 1.91，贝塔系数为 0.42。碧迪医疗公司的 52 周最低价为 218.75 美元，最高价为 269.52 美元。该公司的资产负债比为 0.70，流动比率为 1.85，速动比率为 1.36。</p>
</div><p>Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, topping the consensus estimate of $3.31 by $0.19. The business had revenue of $4.99 billion during the quarter, compared to the consensus estimate of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. Becton, Dickinson and Company's revenue for the quarter was up 2.3% on a year-over-year basis. During the same period in the prior year, the company earned $2.96 EPS. Equities analysts expect that Becton, Dickinson and Company will post 13.1 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>碧迪医疗公司（NYSE:BDX - Get Free Report）于 8 月 1 日星期四公布了季度财报。该医疗器械供应商在该季度报告中每股盈利 3.50 美元，超过了市场预期的 3.31 美元，增加了 0.19 美元。该季度业务收入为 49.9 亿美元，低于市场预期的 50.8 亿美元。碧迪医疗公司的净资产收益率为 14.49%，净利润率为 7.13%。相比去年同期，碧迪医疗公司的季度收入增长了 2.3%。分析师预计，碧迪医疗公司本财年的每股收益将达到 13.1 美元。</p>
</div><h2>Becton, Dickinson and Company Dividend Announcement</h2>
<div class="lb-trans"><h2>碧迪医疗公司宣布股息</h2>
</div><p>The business also recently declared a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Monday, September 9th will be paid a $0.95 dividend. The ex-dividend date is Monday, September 9th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.63%. Becton, Dickinson and Company's payout ratio is currently 83.70%.</p>
<div class="lb-trans"><p>该公司最近宣布了季度股息，将于 9 月 30 日星期一支付。股东登记日为 9 月 9 日星期一，将支付 0.95 美元的股息。除息日为 9 月 9 日星期一。这代表年化股息为 3.80 美元，股息率为 1.63%。碧迪医疗公司的派息比率目前为 83.70%。</p>
</div><h2>Becton, Dickinson and Company Profile (Free Report)</h2>
<div class="lb-trans"><h2>碧迪医疗公司简介（免费报告）</h2>
</div><p>Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.</p>
<div class="lb-trans"><p>碧迪医疗公司在全球范围内为医疗机构、医生、生命科学研究人员、临床实验室、制药行业和普通公众开发、制造和销售医疗用品、设备、实验室设备和诊断产品。该公司分为 BD Medical、BD Life Sciences 和 BD Interventional 三个部门运营。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than Becton, Dickinson and Company</li>
<li>What Are the FAANG Stocks and Are They Good Investments?</li>
<li>Take Advantage of Village Farms Stock as Cannabis Market Evolves</li>
<li>Comparing and Trading High PE Ratio Stocks</li>
<li>MarketBeat Week in Review – 9/16 - 9/20</li>
<li>3 Ways To Invest In Coffee, Other Than Drinking It</li>
<li>Don’t Miss These 3 Retail Stocks for Fall Gains</li>
</ul>
<div class="lb-trans"><h2>精选文章</h2>
<ul>
<li>我们喜欢的五只股票，比碧迪医疗公司更好</li>
<li>什么是 FAANG 股票，它们是好投资吗？</li>
<li>利用村庄农场股票，随着大麻市场的发展</li>
<li>比较和交易高市盈率股票</li>
<li>MarketBeat 周评 - 9/16 - 9/20</li>
<li>投资咖啡的三种方式，除了喝</li>
<li>秋季收益不容错过的 3 只零售股</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding BDX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 BDX 持股的对冲基金？</strong> 访问 HoldingsChannel.com 获取最新的 13F 申报和内部交易信息，了解碧迪医疗公司（NYSE:BDX - Free Report）。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJEWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=BDX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和 MarketBeat 的金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><p>→ The $15 &#34;Insider Secret&#34; That Could Save Your Retirement (From Behind the Markets)(Ad)</p>
<div class="lb-trans"><p>→ 这个价值 15 美元的&#34;内幕秘密&#34;可能拯救您的退休金（来自市场幕后）(广告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NDUx" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9451&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Becton, Dickinson and Company right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资 1,000 美元到碧迪医疗？</h2>
</div><p>Before you consider Becton, Dickinson and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑是否投资碧迪医疗之前，您应该听听这个消息。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 持续追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该购买的股票... 而碧迪医疗并不在名单上。</p>
</div><p>While Becton, Dickinson and Company currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管碧迪医疗目前在分析师中拥有&#34;中等买入&#34;评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Ensign Peak Advisors Inc 在碧迪医疗公司（NYSE: BDX）持有 3655 万美元的股票